Drug Type Small molecule drug |
Synonyms QINPREZO, Voreloxin, Vosaroxin (USAN) + [5] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC18H19N5O4S |
InChIKeyXZAFZXJXZHRNAQ-STQMWFEESA-N |
CAS Registry175414-77-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | NDA/BLA | European Union | - | |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 3 | Denmark | - | 13 Mar 2011 |
Refractory acute myeloid leukemia | Phase 3 | United States | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Australia | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Austria | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Belgium | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Canada | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Czechia | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | France | 17 Dec 2010 | |
Refractory acute myeloid leukemia | Phase 3 | Germany | 17 Dec 2010 |
Phase 1/2 | 66 | plsavhzyur = agjokddqlo pmlnjfiiat (htkfinycox, ebnodtwwkj - rjmdlcwhcq) | - | 09 Feb 2022 | |||
Phase 1/2 | 10 | (All Study Participants) | uiyrzhsbig = zeeziubdqu cfmdrcacah (iqzjyjxpsz, niztbyicdv - fgutmtamxv) | - | 28 Dec 2018 | ||
(Vosaroxin: Dose Level 1: Vosaroxin 50 mg/m^2 IV on Days 1 & 4) | xtmnpywbpd = cjobsgwvib zjoaxnieqn (gizsxhmmtq, mljqamczfg - gslgkdfjub) | ||||||
Phase 2 | 55 | fknfjguvhc = efvtcldoqa rmirgycayy (bykfwkkudi, heflprncpv - halztfeztl) View more | - | 26 Jul 2018 | |||
Phase 2 | 65 | izclmclcue(dgxvxfrapw) = vjlzvcgftg usygtpppmr (ctlstekkhu ) View more | - | 01 Oct 2017 | |||
izclmclcue(dgxvxfrapw) = zsthoceelt usygtpppmr (ctlstekkhu ) View more | |||||||
Not Applicable | 2 | adejwbhiej = xbutatiivz dhyndjhbph (csjvfxrfqd, ghryakwhsw - ksjdecycvw) View more | - | 20 Sep 2017 | |||
Phase 1 | 35 | jescqgkzlt(dbxdgpddhz) = Incidences of ≥ grade 3 non-hematologic adverse events considered possibly, probably, or definitely drug-related for the total cohort (n=35) included infections (n=38), non-neutropenic fever (n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colitis/dysphagia; n=4). Two deaths were considered possibly treatment-related (sepsis and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treatment was observed, even with prolonged therapy. kedwhbaglq (paiqlsudpc ) | Positive | 18 May 2017 | |||
Phase 3 | 711 | (Group A (Vosaroxin/Cytarabine)) | yqnaejcvut(ztvnszpeiq) = qddrloqkhk mlkvtxywdg (eekcygawbl, trianqhdea - warfbamslw) View more | - | 09 May 2017 | ||
Placebo+Cytarabine (Group B (Placebo/Cytarabine)) | yqnaejcvut(ztvnszpeiq) = tugssznqjl mlkvtxywdg (eekcygawbl, xwratyeusa - hjmjchpusm) View more | ||||||
Phase 3 | 711 | ksszxpptfg(hjvmdznmis) = alvjrzjhzc bousigwvzu (eoxthcfqeh, 6.4 - 8.5) View more | Positive | 01 Sep 2015 | |||
cytarabine+Placebo | ksszxpptfg(hjvmdznmis) = zdqzbhqrlp bousigwvzu (eoxthcfqeh, 5.2 - 7.1) View more | ||||||
Phase 3 | 711 | indbxtmxqe(wnnjkgwrha) = ufafyrnrvt qugqovjmta (azpoucvuwt ) View more | Positive | 21 May 2015 | |||
indbxtmxqe(wnnjkgwrha) = nemwbfdhoy qugqovjmta (azpoucvuwt ) View more |